Vanderbilt-Ingram Cancer Center

143 total trials 107 currently recruiting 29 completed

Trial Pipeline

RECRUITING NA

High-Resolution PET-CT Imaging for Surgical Margin Visualization

NCT06915454

RECRUITING Early Phase 1

Window Trial of Fluorescently Labeled Panitumumab (Panitumumab-IRDye800) in Head and Neck Cancer

NCT06819228

RECRUITING NA

Cryodevitalization for the Treatment of Early Stage Lung Cancer, CRYSTAL Trial

NCT06593106

RECRUITING Phase 4

EBUS-TBNA vs Transbronchial Mediastinal Cryobiopsy for Adequacy of Next Generation Sequencing

NCT06105801

RECRUITING Phase 1

Eltanexor and Venetoclax in Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia

NCT06399640

RECRUITING Phase 4

Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors

NCT06016855

RECRUITING Phase 2

Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers

NCT05919108

RECRUITING Phase 1

Phase I/II Trial in ES-SCLC to Enhance Response to Atezolizumab Plus Chemotherapy With Total Body Irradiation

NCT06110572

RECRUITING

A Combined Biomarker Model for Risk Stratification of Indeterminate Pulmonary Nodules

NCT06074133

RECRUITING Phase 1

Evaluating the Use of Dual Imaging Techniques for Detection of Disease in Patients With Head and Neck Cancer

NCT05945875

RECRUITING Phase 1

Evaluating 111In Panitumumab for Nodal Staging in Head and Neck Cancer

NCT05901545

RECRUITING Phase 2

Circulating Tumor DNA to Guide Changes in Standard of Care Chemotherapy

NCT05770531

RECRUITING Early Phase 1

Image-Based, In-Vivo Assessment of Tumor Hypoxia to Guide Hypoxia-Driven Adaptive Radiation Therapy

NCT05996432

RECRUITING Phase 1

Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer

NCT05501665

RECRUITING Phase 2

Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study

NCT05361720

RECRUITING

Cohort to Augment the Understanding of Sarcoma Survivorship Across the Lifespan

NCT06482957

RECRUITING Phase 2

Hypofractionated Radiotherapy Followed by Surgical Resection in the Treatment of Soft Tissue Sarcomas

NCT04506008

RECRUITING

The Clonal Hematopoiesis & Inflammation in Vasculature Registry and Biorepository

NCT06701214

RECRUITING

Studying Health Outcomes After Treatment in Patients With Retinoblastoma

NCT03932786

RECRUITING

Inherited CAncer REgistry

NCT03231891

RECRUITING

Low-Dose Total Skin Electron Therapy in Treating Patients With Refractory or Relapsed Stage IB-IIIA Mycosis Fungoides

NCT02702310

RECRUITING

Storage and Research Use of Human Bio-specimens From Melanoma Patients and Clinical Testing for Assignment of Treatment

NCT01205815

RECRUITING

Collecting and Storing Tissue Samples From Women With or Without Breast Cancer

NCT00899301

RECRUITING

Collecting and Analyzing Tissue Samples From Patients Undergoing Surgery for Non-Small Cell Lung Cancer

NCT00897117

ACTIVE NOT RECRUITING NA

Biomarker Platform (Virtual Nodule Clinic) for the Management of Indeterminate Pulmonary Nodules

NCT06638398

ACTIVE NOT RECRUITING NA

Improving Care After Inherited Cancer Testing

NCT04763915

ACTIVE NOT RECRUITING

COVID-19 and Cancer Consortium Registry

NCT04354701

ACTIVE NOT RECRUITING Phase 2

Ifetroban in Treating Patients With Malignant Solid Tumors at High Risk of Metastatic Recurrence

NCT03694249

ACTIVE NOT RECRUITING

Early Detection of Lung Cancer

NCT03181256

ACTIVE NOT RECRUITING Phase 1

BYL719 and Letrozole in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer

NCT01791478

ACTIVE NOT RECRUITING

Nashville Early Diagnosis Lung Cancer Project

NCT01475500

COMPLETED NA

Navigation Endoscopy to Reach Indeterminate Lung Nodules Versus Trans-Thoracic Needle Aspiration

NCT04250194

COMPLETED NA

Visually Enhanced Education About Prostate Cancer

NCT02846870

COMPLETED

Skin/Soft Tissue Elasticity in Head and Neck Cancer Survivors With Lymphedema and Fibrosis

NCT02676752

COMPLETED Phase 1

Galunisertib and Paclitaxel in Treating Patients With Metastatic Androgen Receptor Negative (AR-) Triple Negative Breast Cancer

NCT02672475

COMPLETED NA

Impact of Pleural Manometry on Chest Discomfort After Therapeutic Thoracentesis

NCT02677883

COMPLETED Phase 1

TGR-1202 + Ruxolitinib PMF PPV-MF PET-MF MDS/MPN Polycythemia Vera Resistant to Hydroxyurea

NCT02493530

COMPLETED NA

Pain Management Smartphone Application for Patients With Stage III-IV Head and Neck Cancer Undergoing Radiation Therapy

NCT02324881

COMPLETED NA

Programs to Support You During Chemotherapy (Pro-You)

NCT02148406

COMPLETED NA

ALL-Active: A Family-Based Lifestyle Program for Pediatric Acute Leukemia Patients

NCT01901367

COMPLETED Phase 1

Molecular Determinants Affecting Fluoro-L-thymidine (FLT) Positron Emission Tomography (PET) in Rectal Cancer

NCT01207895

COMPLETED Phase 1

Gemcitabine Hydrochloride, Oxaliplatin, and Erlotinib Hydrochloride in Treating Patients With Advanced Biliary Tract Cancer, Pancreatic Cancer, Duodenal Cancer, or Ampullary Cancer

NCT00987766

COMPLETED Phase 2

Bendamustine as Second-Line Therapy in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer

NCT00984542

COMPLETED Phase 2

Cisplatin and Paclitaxel With or Without Everolimus in Treating Patients With Stage II or Stage III Breast Cancer

NCT00930930

COMPLETED Phase 2

Sorafenib and Erlotinib in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery

NCT00837876

COMPLETED

Molecular Markers in Predicting Lung Cancer Development Using Tissue Samples From Healthy Participants

NCT00899457

COMPLETED Phase 2

Fluorouracil, Oxaliplatin, and Leucovorin in Treating Patients With Metastatic Stomach Cancer or Gastroesophageal Junction Cancer

NCT00514020

COMPLETED

Pain Control in Hospice Patients With Cancer-Related Pain

NCT00609297

COMPLETED

Blood Proteins in Predicting Treatment Benefit in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer

NCT00896675

COMPLETED NA

Healing Touch in Treating Fatigue in Women Undergoing Radiation Therapy for Breast Cancer

NCT00574145

COMPLETED

Developing Mouse Models of Breast Cancer Using Tissue Samples From Women With Breast Cancer

NCT00897468

COMPLETED

Opioid Titration in the Hospice Setting: Barriers Assessment and Modification of the Model Order Sheet and Protocol

NCT01230515

COMPLETED

Growth Factor Levels in the Blood of Patients Undergoing Radiation Therapy for Epithelial Cancer

NCT00897793

COMPLETED Phase 1

Erlotinib and Everolimus in Treating Patients With Metastatic Breast Cancer

NCT00574366

COMPLETED

Protein and RNA Expression Patterns in Predicting Response to Treatment in Patients With Lung Cancer

NCT00897650

COMPLETED Phase 3

Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain

NCT00666211

COMPLETED Phase 2

Erlotinib and Bevacizumab in Treating Patients With Stage IV Melanoma

NCT00466687

COMPLETED Phase 2

Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer

NCT00416650

COMPLETED NA

Paclitaxel and Radiation Therapy in Treating Patients Undergoing Surgery for Stage II or Stage III Breast Cancer

NCT00647218

COMPLETED Phase 2

Trastuzumab Plus Docetaxel in Treating Women With Recurrent or Metastatic Breast Cancer

NCT00006104

What the Pipeline for Vanderbilt-Ingram Cancer Center Shows

According to the ClinicalTrials.gov registry, Vanderbilt-Ingram Cancer Center is linked to 143 US clinical trials across every stage of research activity. Of those, 107 studies are currently recruiting — about 75% of the sponsor's indexed portfolio — and 29 are already marked complete, representing roughly 20% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.

The phase mix for Vanderbilt-Ingram Cancer Center reports 3 late-stage studies (Phase 3 and Phase 4 combined) and 53 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.

The top therapeutic focus area indexed for Vanderbilt-Ingram Cancer Center is Lung Cancer with 10 linked trials, and 9 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial